Changes in Hong Kong stocks | Hutchison Pharmaceuticals (00013) rose nearly 6%, Teresa® and Warisa® combination therapy showed clinically significant remission rates

The Zhitong Finance App learned that Hewang Pharmaceutical (00013) rose nearly 6%. As of press release, it had risen 5.92% to HK$32.2, with a turnover of HK$543.41 million.

^{According to the news, recently, Chi-Med announced the positive summary results of the SAVANNAH Phase II study. The combination therapy of TARISSA ® (TAGRISSO®, osimertinib) and ORPATHYS® (ORPATHYS®, savolitinib) has previously received Terry} A high, clinically significant, and long-lasting objective response rate (ORR) improvement was shown in non-small cell lung cancer patients with advanced levels of mesenchymal epithelial conversion factor overexpression and/or amplification (defined as IHC90+ and/or FISH10+) after treatment with SA ^®. The above data will be presented at an upcoming academic conference and shared with global regulators.

According to reports, Warisal is a potent and highly selective oral MET tyrosine kinase inhibitor (TKI). It was jointly developed by AstraZeneca (AZN.US) and Hewang Pharmaceuticals, and commercialized by AstraZeneca. It has been approved in China to treat patients with non-small cell lung cancer with MET exon 14 jump mutations whose disease progresses after systemic treatment or who are unable to receive chemotherapy.

According to Northeast Securities, the initial positive ORR results of the SAVANNAH study were announced at the 2022 WCLC conference. Among all patients with high MET levels, the ORR reached 49%. The clinical results announced this time also showed high ORR improvements, and continued to demonstrate the competitiveness of post-line treatment with sevotinib combination therapy. Partner AstraZeneca plans to submit a marketing application to the FDA before the end of the year. It has previously obtained fast-track qualifications. Sevotinib is expected to be approved as the company's second overseas product after fruquintinib, and will continue to expand overseas markets.